Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects.

Topic Healthy Subjects
Compound 5-MeO-DMT
Country United Kingdom
Visit trial
Status Recruiting
Results Published
Start date 15 September 2021
End date 16 March 2022
Design Blinded
Type Interventional
Generation Second
Participants 42
Sex All
Age 18- 99
Therapy No

Trial Details

A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects

Trial Number NCT05032833

Sponsors & Collaborators

King's College London
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is one of Europe's top centres for mental health and related neurosciences research.

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.